In a prospective, non-randomized study, 23 women with advanced breast cancer took oral beta-(1,3)(1,6)-D-glucan for 15 days; 16 healthy women provided baseline comparison samples. Patient monocyte counts and expression of selected activation markers increased between day 0 and day 15. The study measured short-term immune markers, not tumor response, symptoms, survival, or treatment efficacy. Its small uncontrolled design and incompletely specified product source prevent conclusions about cancer benefit or an Aureobasidium-specific effect.
Twenty-three patients took oral beta-glucan for 15 days, with immune markers measured before and after.
Monocyte counts and selected activation markers increased.
The uncontrolled study did not measure or prove a cancer-treatment outcome.
AI-generated summary for accessibility. Always refer to the original paper.
Demir G., Klein H., Mandel-Molinas N., Tuzuner N.. Beta glucan induces proliferation and activation of monocytes in peripheral blood of patients with advanced breast cancer. International Immunopharmacology. 2007. DOI: 10.1016/j.intimp.2006.08.011.
For scientific reference only. Not medical advice. Consult a qualified healthcare professional. See our Medical Disclaimer.